The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report

作者全名："Deng, Wang; Chen, Juan; Deng, Xin-Yu"

作者地址："[Deng, Wang; Chen, Juan; Deng, Xin-Yu] Chongqing Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Chongqing, Peoples R China; [Deng, Wang; Chen, Juan] Med Res Ctr Pulm & Crit Care Med, Dept Pulm Med, Chongqing, Peoples R China"

通信作者："Deng, W (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Chongqing, Peoples R China.; Deng, W (通讯作者)，Med Res Ctr Pulm & Crit Care Med, Dept Pulm Med, Chongqing, Peoples R China."

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001183665300001

JCR分区：Q1

影响因子：7.3

年份：2024

卷号：15

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：atezolizumab; anlotinib; asthma; small-cell lung cancer; combined regimens

摘要："Background Extensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a characteristically short survival period and extremely poor prognosis. A combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs can achieve promising efficacy and safety in patients with ES-SCLC as a second-line or subsequent treatment, extending survival to some extent. However, the clinical outcomes remain mostly unsatisfactory and are sometimes affected by treatment-related adverse events.Case presentation A 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.Conclusions This is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored."

基金机构：Chongqing Science and Health Joint Medical Research Project [2023MSXM091]; Senior Medical Talents Program of Chongqing for Young and Middle-Aged [2020219]; Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University [202124]

基金资助正文："The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by Chongqing Science and Health Joint Medical Research Project(No.2023MSXM091),Senior Medical Talents Program of Chongqing for Young and Middle-Aged (No.2020219) and Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University(No.202124)."